Fig. 4: Muscle-specific GSK3 knockdown (mdx/GSK3KD) in 4–6 week-old and 10–14 week-old mdx mice improves muscle performance. | Nature Communications

Fig. 4: Muscle-specific GSK3 knockdown (mdx/GSK3KD) in 4–6 week-old and 10–14 week-old mdx mice improves muscle performance.

From: GSK3 inhibition improves skeletal muscle function and whole-body metabolism in male mouse models of Duchenne muscular dystrophy

Fig. 4: Muscle-specific GSK3 knockdown (mdx/GSK3KD) in 4–6 week-old and 10–14 week-old mdx mice improves muscle performance.The alternative text for this image may have been generated using AI.

a–c GSK3α and GSK3β content are lower in 4–6 week old and 10–14 week-old mdx/GSK3KD mice compared with their respective mdx counterparts (mdx, n = 3 and mdx/GSK3KD n = 4). d–e Twitch and tetanic force production of the EDL is improved in 4–6 week-old and 10–14 week old mdx/GSK3KD mice compared with mdx mice (4–6 weeks mdx, n = 7 and mdx/GSK3KD n = 6; 10–14 weeks mdx, n = 4 and mdx/GSK3KD n = 6). f, g EDL muscle fatigue is improved in mdx/GSK3KD mice at 4–6 weeks and 10–14 weeks of age with a rightward shift in the fatigue curve (4–6 weeks mdx, n = 7 and mdx/GSK3KD n = 8; 10-14 weeks mdx, n = 4 and mdx/GSK3KD n = 6). h mdx/GSK3KD mice have lower serum creatine kinase (CK) (U/L) than mdx mice at 4–6 weeks, but not at 10–14 weeks (4–6 weeks mdx, n = 7 and mdx/GSK3KD n = 6; 10–14 weeks mdx, n = 4 and mdx/GSK3KD n = 6). For (b–e and h), a two-way ANOVA was used to assess the main effects of genotype and age. For (f, g), a two-way ANOVA was used to assess the main effects of genotype and time. All values are mean ± SEM. Significant main effects and interaction terms are denoted in the text above. *p < 0.05, **p < 0.01.

Back to article page